Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalteparin and Gemcitabine in Unresectable Pancreatic Cancer
NCT00031837Phase 3Terminated
- Start
- Oct 2002
- Primary completion
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dalteparin in pancreatic cancer (PC) (2 arms). Primary endpoint: Quality of Life. Started Oct 2002; status: terminated.
02
Drugs
dalteparin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00031837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031837.